{"disease":{"id":"her2-low-breast-cancer","name":"her2 low breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05945732","title":"DESTINY Breast Respond HER2-low Europe","phase":"","overall_status":"RECRUITING","enrollment_count":1155,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT06040593","title":"Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":927,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06210776","title":"A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06533826","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":357,"lead_sponsor_name":"Ana C Garrido-Castro, MD","has_results":false},{"nct_id":"NCT07358182","title":"Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05904964","title":"Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05466786","title":"Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":255,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07317778","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":249,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07203729","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":184,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06144944","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT07383818","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07132749","title":"NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Yeon Hee Park","has_results":false},{"nct_id":"NCT06340230","title":"SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT07287917","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"Aminex Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06830382","title":"HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Renske Altena","has_results":false},{"nct_id":"NCT06433804","title":"Clinicopathological Parameters of HER2 Low Breast Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Vardhman Mahavir Medical College And Safdarjung Hospital","has_results":false},{"nct_id":"NCT07198724","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Sarah Sammons, MD","has_results":false},{"nct_id":"NCT05795101","title":"TRUDI: TDXD+Durva in HER2+/Low IBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Filipa Lynce, MD","has_results":false},{"nct_id":"NCT06832202","title":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05165225","title":"Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07446452","title":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06224673","title":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Laura Huppert, MD, BA","has_results":false},{"nct_id":"NCT06733233","title":"A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT06386263","title":"HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02598427","title":"Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Kimberly Blackwell","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}